Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/bjd/ljad206 | DOI Listing |
Oncoimmunology
December 2024
Cancer Department, Biobizkaia Health Research Institute, Barakaldo, Spain.
Immune checkpoint inhibitors in combination with tyrosine kinase inhibitors (TKIs) are improving the response rates of advanced renal cancer patients. However, many treated patients do not respond, making novel immune checkpoint-based immunotherapies potentially clinically beneficial only for specific groups of patients. We detected high expression of the immune checkpoint protein B7-H3 in clear cell renal cell carcinomas (ccRCCs) and evaluated B7-H3 immunohistochemistry staining in tissue microarray samples from two distinct renal cancer cohorts.
View Article and Find Full Text PDFGeorgian Med News
September 2024
Department of Pathology and Poultry Disease, College of Veterinary Medicine, University of Baghdad, Iraq.
The addressing this question in udder tissue (main target of the metal) and test here if uranium U at low concentrations could also be a pro-oxidant. The research deals with different groups of grass-fed cows in several locations where the same phenomenon represents a case from Basra/Iraq. The histopathological examination of the udder in cows with (U) revealed hemangiomatous transformation.
View Article and Find Full Text PDFInt J Surg Pathol
November 2024
The Institute of Liver Disease & Transplantation, Dr Rela Institute & Medical Centre, Chennai, Tamil Nadu, India.
. Neutrophil-rich hepatocellular carcinoma (HCC) is an extremely uncommon subtype of HCC with an overall incidence of <1%. Neutrophil-rich HCC shows poor cellular differentiation and sarcomatoid transformation in most patients.
View Article and Find Full Text PDFJ Transl Int Med
November 2024
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Histological transformation from lung adenocarcinoma (ADC) to small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SCC), and sarcomatoid carcinoma (PSC) after targeted therapies is recognized as a mechanism of resistance in ADC treatments. Patients with transformed lung cancer typically experience a poor prognosis and short survival time. However, effective treatment options for these patients are currently lacking.
View Article and Find Full Text PDFFront Immunol
November 2024
Department of Oral and Maxillofacial Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!